{
  "report_rows": [
    {
      "kpi": "Adjusted EPS",
      "prediction": "BEAT",
      "answer": "pred ~$3.92 vs. cons $3.85",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Adjusted operating income",
      "prediction": "BEAT",
      "answer": "pred ~$590M vs. cons $580.5M",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Treatments",
      "prediction": "IN-LINE",
      "answer": "pred ~7.235M vs. cons 7.215M",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY2026 adjusted operating income",
      "prediction": "LOWER",
      "answer": "guide $2.15B-$2.25B vs. cons $2.244B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 adjusted EPS",
      "prediction": "LOWER",
      "answer": "guide $14.10-$15.20 vs. cons $14.88",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 treatment-volume growth",
      "prediction": "UNCHANGED",
      "answer": "guide +25-50 bps vs. ~+25-50 bps implied by consensus",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": -7.0,
  "day1_confidence": "LOW",
  "day5_residual_pct": -8.0,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "FOLLOW-THROUGH \u2014 maintained FY guide implies out-period estimate pressure",
  "day5_confidence": "LOW"
}